A phase IV Post-Approval Safety Study of ELPIDA®
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Elsulfavirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 07 Jan 2019 New trial record
- 21 Dec 2018 According to a Viriom media release, to date 300 of planned 2000 patients have completed 24 weeks of treatment in this study. Additional clinical studies have been initiated to assess safety and efficacy of Elpida in HIV-infected persons with comorbidities and when co-administered with other drugs.